Sign in
HRMY Stock Price, Chart, Stats & News
Harmony Biosciences Holdings, Inc.
Save
1.99B
Market cap
13.90x
Current P/E
11.25x
Forward P/E
HRMY chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 77.16% |
Operating margin | 24.00% |
Pretax margin | 24.76% |
Net margin | 18.27% |
Effective tax rate | 26.21% |
ROA | 12.48% |
ROE | 19.84% |
D/E | 0.28x |
Interest coverage ratio | 14.23x |
HRMY valuation
P/E | 13.90x |
P/S | 1.77x |
P/B | 1.76x |
P/CF | 4.39x |
P/FCF | 4.41x |
P/OCF | 4.39x |
PEG | -0.65x |
EV multiple | 8.15x |
About
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020.
Similar securities
Based on sector and market capitalization
Report issue